For Q3 of the fiscal year ending March 2026, net sales were \u00a530,353 million (up 17.3% YoY), operating income was \u00a5427 million, and net income attributable to owners of parent for the quarter was \u00a51,744 million.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4552","jir_company_name":"JCR Pharmaceuticals Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-01-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4552-20260128-01.pdf","jir_short_summary":"For Q3 of the fiscal year ending March 2026, net sales were \u00a530,353 million (up 17.3% YoY), operating income was \u00a5427 million, and net income attributable to owners of parent for the quarter was \u00a51,744 million.","jir_summary":"### Overview of Business Results\nConsolidated net sales for Q3 of the fiscal year ending March 2026 reached \u00a530,353 million (up 17.3% YoY), driven by strong performance of the mucopolysaccharidosis type II treatment 'Izcargo\u00ae Injection 10mg'. Meanwhile, the recombinant human growth hormone preparation 'Growject\u00ae' saw lower sales due to price revisions. Overall, revenue increased significantly, supported by a substantial rise in contract income. Operating income was \u00a5427 million, ordinary income \u00a5711 million, and net income attributable to owners of parent for the quarter was \u00a51,744 million, turning profitable from losses in the same period last year. R&D expenses amounted to \u00a513,372 million (increased YoY), reflecting contract upfront payments related to exclusive licensing rights acquisitions.\n\n### Financial Position and Revision to Earnings Forecast\nAt the end of the Q3 consolidated period, total assets were \u00a5113,306 million, total liabilities \u00a566,555 million, and total net assets \u00a546,750 million, with an equity ratio of 40.8%, down 4.0 points from the end of the previous fiscal year. The full-year earnings forecast has been revised, with net sales increased to \u00a539,500 million by \u00a51,700 million. However, due to higher R&D and selling, general and administrative expenses, operating income is lowered to \u00a5400 million, ordinary income to \u00a5400 million, and net income attributable to owners of parent to \u00a51,600 million. The dividend forecast remains unchanged.","jir_financial_highlights":"Net Sales: \u00a530,353 million (Up 17.3% YoY)\nOperating Income: \u00a5427 million (Turned to black from operating loss of \u00a5754 million year ago)\nOrdinary Income: \u00a5711 million (Turned to black from ordinary loss of \u00a51,380 million year ago)\nNet Income Attributable to Owners of Parent for the Quarter: \u00a51,744 million (Turned to black from net loss of \u00a5576 million year ago)\nEquity Ratio: 40.8% (Down 4.0 points from the end of previous consolidated fiscal year)\nNumber of Shares Outstanding (Including Treasury Stock): 129,686,308 shares (Unchanged from end of previous fiscal year)\nTreasury Stock at Fiscal Year-End: 7,699,902 shares (Decreased from 7,851,002 shares at previous fiscal year-end)\nResearch and Development Expenses: \u00a513,372 million (Increased by \u00a53,447 million YoY)\nFull-Year Earnings Guidance Net Sales: \u00a539,500 million (Up \u00a51,700 million from previous forecast)\nFull-Year Earnings Guidance Operating Income: \u00a5400 million (Down \u00a52,200 million from previous forecast)\nFull-Year Earnings Guidance Net Income Attributable to Owners of Parent: \u00a51,600 million (Down \u00a51,400 million from previous forecast)","jir_category":"","jir_hashtags":"#JCRPharmaceuticals, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: \u00a530,353 million (up 17.3% YoY)\nOperating Income: \u00a5427 million (turned profitable from operating loss of \u00a5754 million year ago)\nNet Income Attributable to Owners of Parent for the Quarter: \u00a51,744 million (turned profitable from net loss of \u00a5576 million year ago)","jir_meta_title":"JCR Pharmaceuticals Co., Ltd. Q3 Fiscal Year March 2026 Financial Summary - 17.3% Sales Increase and Return to Profit","jir_meta_description":"Q3 financial summary of JCR Pharmaceuticals Co., Ltd. for fiscal year ending March 2026. Net sales increased 17.3% YoY to \u00a530,353 million, operating income at \u00a5427 million, and net income attributable to owners of parent at \u00a51,744 million turning profitable. Full-year earnings forecast revised.","jir_og_title":"JCR Pharmaceuticals Q3 FY2026 Financial Results - Sales Up 17.3% and Returned to Profit","jir_og_description":"JCR Pharmaceuticals Co., Ltd. Q3 financial summary for fiscal year ending March 2026. Net sales rose 17.3% YoY, operating income turned positive, and net income significantly increased.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Trend (Millions of Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[25880,30353],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Millions of Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[-754,427],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}, {\"jir_chart_id\": \"ordinary_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Ordinary Income Trend (Millions of Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Ordinary Income\\\",\\\"data\\\":[-1380,711],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}, {\"jir_chart_id\": \"net_income_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent for the Quarter Trend (Millions of Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[-576,1744],\\\"backgroundColor\\\":\\\"#76b7b2\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Sales Composition by Product (Q3 FY2026)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Growject\u00ae\\\",\\\"Izcargo\u00ae Injection\\\",\\\"Epoetin Alfa BS Injection 'JCR'\\\",\\\"Darbepoetin Alfa BS Injection 'JCR'\\\",\\\"Temcell\u00ae HS Injection\\\",\\\"Agalsidase Beta BS Injection 'JCR'\\\",\\\"Contract Income\\\"],\\\"datasets\\\":[{\\\"data\\\":[13539,5179,1250,2346,2212,863,5249],\\\"backgroundColor\\\":[\\\"#4e79a7\\\",\\\"#f28e2b\\\",\\\"#e15759\\\",\\\"#76b7b2\\\",\\\"#59a14f\\\",\\\"#edc949\\\",\\\"#af7aa1\\\"]}]},\\\"options\\\":{}}\"}]","ir_related_company":9680,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-21425","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n